Are nintedanib ethanesulfonate soft capsules made in China?

The original drug Nintedanib (Nintedanib) was developed by Boehringer Ingelheim and has been marketed in many countries and regions around the world for the treatment of idiopathic pulmonary fibrosis and other indications. The original drug of nintedanib ethanesulfonate soft capsules has been launched in China. According to earlier information, the drug was approved for marketing in China in September 2017 for the treatment of systemic sclerosis-related interstitial lung disease and idiopathic pulmonary fibrosis. It has since become one of the important treatment options available in the country, providing new treatment avenues for patients.

In recent years, with the continuous improvement of domestic pharmaceutical technology, China has also successfully developed a domestic version of nintedanib ethanesulfonate. Judging from the drug approval number, the domestically produced nintedanib ethanesulfonate soft capsules have been approved by the State Food and Drug Administration and are qualified for legal sales in the domestic market. These domestic drugs are produced in strict accordance with national drug production standards and have passed strict quality testing to ensure the safety and effectiveness of the drugs.

Many domestic pharmaceutical companies have produced nintedanib ethanesulfonate soft capsules. During the production process, these companies focus on the selection of raw materials and optimization of processes to ensure the quality and efficacy of drugs. Common manufacturers may include CSPC, Qilu Pharmaceutical, etc. In addition, the price of domestically produced nintedanib ethanesulfonate soft capsules is more affordable than imported drugs, making this treatment affordable for more patients. This not only reduces the financial burden on patients, but also makes a positive contribution to the domestic medical and health industry.

In general, nintedanib ethanesulfonate soft capsules already have domestic versions, and these domestic drugs have certain advantages in terms of quality, efficacy and price. This provides more treatment options for domestic patients and promotes the development of the domestic pharmaceutical industry.